Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Viking Pharmaceutical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$2,285,626

229 payments

Through program year 2025, Viking Pharmaceutical Trials Inc is reported as receiving $2,285,626 in research payments, across 229 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $519,466 78
2024 Research $285,190 16
2023 Research $135,152 32
2022 Research $391,134 33
2021 Research $516,338 35
2020 Research $380,140 32
2019 Research $58,206 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $563,551 17 payments
  2. Sage Therapeutics, Inc. $502,098 63 payments
  3. AbbVie, Inc. $309,811 40 payments
  4. Janssen Research & Development, LLC $301,115 40 payments
  5. ITI, Inc. $168,818 34 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $148,489 5 payments
  7. Sumitomo Pharma America, Inc. $143,548 5 payments
  8. Supernus Pharmaceuticals, Inc. $119,036 20 payments
  9. Vanda Pharmaceuticals Inc. $29,161 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $186,357 17 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $180,713 4 payments
  3. A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) $167,608 25 payments
  4. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $152,281 19 payments
  5. A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder $143,548 5 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $142,638 2 payments
  7. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $141,732 16 payments
  8. A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $133,507 15 payments
  9. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $119,036 20 payments
  10. Proof of concept and DRF in MDD $116,081 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record